NervGen Pharma Corp.

NGENF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$24,006-$22,382-$20,722-$12,727
Dep. & Amort.$84$145$115$43
Deferred Tax$0$0-$2,596$0
Stock-Based Comp.$5,796$6,045$2,775$4,016
Change in WC$839-$240$2,115$430
Other Non-Cash$447$5,137$529-$31
Operating Cash Flow-$16,841-$11,296-$17,784-$8,269
Investing Activities
PP&E Inv.$0-$6-$21-$45
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$59-$133$0-$0
Investing Cash Flow$59-$139-$21-$45
Financing Activities
Debt Repay.-$101-$101-$76$0
Stock Issued$23,012$867$19,763$18,902
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$216$867$2,954$712
Financing Cash Flow$22,695$766$22,641$19,613
Forex Effect-$305-$124$687$31
Net Chg. in Cash$5,608-$10,792$5,523$11,330
Supplemental Information
Beg. Cash$11,660$22,452$16,929$5,599
End Cash$17,267$11,660$22,452$16,929
Free Cash Flow-$16,841-$11,437-$17,805-$8,314